Literature DB >> 32476879

Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?

Human Adams1,2, Rob van Rooij3, Coline H M van Moorsel1,4, Marcela Spee-Dropkova5, Jan C Grutters1,4, Ruth G Keijsers6.   

Abstract

Currently FDG PET/CT is used as a tool for detection of active sites of sarcoidosis. Routine clinical practice relies on qualitative assessment with visual interpretation. When semi quantitatively expressed, e.g. for scientific purposes, this often leads to dichotomous "positive" or "negative" results. Metabolic activity in the lungs or mediastinum can also be expressed by SUVmax, but this measure is based only on the intensity of a single voxel. Likely for this reason these parameters show poor correlation with variables such as serum biomarkers and suboptimally predict clinical response to treatment. The current study focusses on new volumetric quantification methods for FDG PET/CT. Specifically the percentage of lung volume with increased metabolic activity, "%SUV-high", and the average metabolic activity in the lung "SUVmean", shows significantly better correlation with conventional biomarkers for disease activity than PET dichotomous and SUVmax. Our proposed quantification method needs subsequent and larger studies, however it may open new possibilities for future quantitative research in lung inflammation, and improve precision medicine in sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 44-54). Copyright:
© 2018.

Entities:  

Keywords:  FDG PET; SUVmax; inflammation; quantitative; sarcoidosis; volumetric

Year:  2018        PMID: 32476879      PMCID: PMC7170065          DOI: 10.36141/svdld.v35i1.5807

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  23 in total

1.  18F-FDG PET as a predictor of pulmonary function in sarcoidosis.

Authors:  R G Keijsers; E J Verzijlbergen; J M van den Bosch; P Zanen; E M van de Garde; W J Oyen; J C Grutters
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2011-10       Impact factor: 0.670

2.  Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation.

Authors:  J G SCADDING
Journal:  Br Med J       Date:  1961-11-04

Review 3.  Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis.

Authors:  Kyoungjune Pak; Gi Jeong Cheon; Hyun-Yeol Nam; Seong-Jang Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  J Nucl Med       Date:  2014-04-21       Impact factor: 10.057

4.  High resolution computed tomography in 2-year follow-up of Stage I sarcoidosis.

Authors:  D Ziora; K Kornelia; D Jastrzebski; L Labus; K Zieleznik; J Kozielski
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

Review 6.  Pathology of sarcoidosis.

Authors:  Yale Rosen
Journal:  Semin Respir Crit Care Med       Date:  2007-02       Impact factor: 3.119

7.  Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.

Authors:  R L M Mostard; S Vöö; M J P G van Kroonenburgh; J A Verschakelen; P A H M Wijnen; P J Nelemans; R J Erckens; M Drent
Journal:  Respir Med       Date:  2011-09-06       Impact factor: 3.415

8.  Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults.

Authors:  Dong Soo Lee; Hyejin Kang; Heejung Kim; Hyojin Park; Jungsu S Oh; Jae Sung Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-20       Impact factor: 9.236

9.  Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.

Authors:  Adriane D M Vorselaars; Anouk Verwoerd; Coline H M van Moorsel; Ruth G M Keijsers; Ger T Rijkers; Jan C Grutters
Journal:  Eur Respir J       Date:  2013-08-29       Impact factor: 16.671

10.  A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Authors:  Rémy L M Mostard; Sander M J Van Kuijk; Johny A Verschakelen; Marinus J P G van Kroonenburgh; Patty J Nelemans; Petal A H M Wijnen; Marjolein Drent
Journal:  BMC Pulm Med       Date:  2012-09-14       Impact factor: 3.317

View more
  1 in total

Review 1.  Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.

Authors:  Raisa Kraaijvanger; Montse Janssen Bonás; Adriane D M Vorselaars; Marcel Veltkamp
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.